LGT Fund Management Co Ltd. Reduces Holdings in Boston Scientific Corporation $BSX

LGT Fund Management Co Ltd. trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX) by 10.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 52,466 shares of the medical equipment provider’s stock after selling 5,838 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Boston Scientific were worth $5,635,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. 1248 Management LLC purchased a new stake in shares of Boston Scientific during the first quarter worth approximately $26,000. Y.D. More Investments Ltd purchased a new stake in Boston Scientific in the 1st quarter valued at $27,000. Sound Income Strategies LLC grew its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new stake in Boston Scientific in the 2nd quarter valued at $37,000. Finally, Activest Wealth Management grew its holdings in Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 373 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX opened at $97.30 on Friday. The stock’s 50-day moving average price is $102.93 and its 200 day moving average price is $102.05. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a market cap of $144.17 billion, a price-to-earnings ratio of 57.91, a PEG ratio of 2.32 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 EPS. Boston Scientific’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 in the last 90 days. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on BSX shares. Needham & Company LLC restated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a report on Wednesday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Saturday, September 27th. Leerink Partners upped their target price on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. Finally, Erste Group Bank cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $120.79.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.